Cargando…

Correction to: SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease

Detalles Bibliográficos
Autores principales:	Zou, Honghong, Zhou, Baoqin, Xu, Gaosi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844178/ https://www.ncbi.nlm.nih.gov/pubmed/29523130 http://dx.doi.org/10.1186/s12933-018-0676-1

Ejemplares similares

SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
por: Zou, Honghong, et al.
Publicado: (2017)

Correction to: Early versus late initiation of renal replacement therapy impacts mortality in patients with acute kidney injury post cardiac surgery: a meta-analysis
por: Zou, Honghong, et al.
Publicado: (2019)

Correction: Comparison of SGLT2 inhibitors with DPP4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus
por: Lyu, Young Sang, et al.
Publicado: (2023)

Correction: The optimal time of initiation of renal replacement therapy in acute kidney injury: A meta-analysis
por: Luo, Kaiping, et al.
Publicado: (2018)

A Novel Choice to Correct Inflammation-Induced Anemia in CKD: Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat
por: Yan, Zhipeng, et al.
Publicado: (2020)

Early versus late initiation of renal replacement therapy impacts mortality in patients with acute kidney injury post cardiac surgery: a meta-analysis
por: Zou, Honghong, et al.
Publicado: (2017)

Correction: Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
por: Chang, Yoon-Kyung, et al.
Publicado: (2016)

Correction to: SGLT2 inhibitors and lower limb complications: an updated meta-analysis
por: Lin, Chu, et al.
Publicado: (2021)

Correction to: METTL14 promotes glomerular endothelial cell injury and diabetic nephropathy via m6A modification of α‑klotho
por: Li, Manna, et al.
Publicado: (2022)

Correction: Aliskiren therapy in hypertension and cardiovascular disease: a systematic review and a meta-analysis
por: Fu, Shufang, et al.
Publicado: (2018)

Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease
por: Dai, Zhi-Cheng, et al.
Publicado: (2023)

New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors
por: Dekkers, Claire C. J., et al.
Publicado: (2018)

Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy
por: Zou, Honghong, et al.
Publicado: (2019)

Management of anticoagulation and antiplatelet therapy in patients with primary membranous nephropathy
por: Zou, Honghong, et al.
Publicado: (2019)

Correction to: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
por: Ali, Amar, et al.
Publicado: (2019)

SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease
por: Podestà, Manuel Alfredo, et al.
Publicado: (2023)

Correction to: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta‑analysis
por: Li, Hang-Long, et al.
Publicado: (2021)

SGLT inhibitor adjunct therapy in type 1 diabetes
por: McCrimmon, Rory J., et al.
Publicado: (2018)

Renoprotective effects of combined SGLT2 and ACE inhibitor therapy in diabetic Dahl S rats
por: Kojima, Naoki, et al.
Publicado: (2015)

The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status
por: Matthews, Jennifer, et al.
Publicado: (2023)

Optimal use of SGLT2 inhibitors in diabetic kidney transplant recipients
por: Pham, Phuong-Thu T., et al.
Publicado: (2022)

Comparative Efficacy and Safety of Therapies in IgA Nephropathy: A Network Meta-analysis of Randomized Controlled Trials
por: Yang, Pingping, et al.
Publicado: (2018)

Antioxidant Roles of SGLT2 Inhibitors in the Kidney
por: Llorens-Cebrià, Carmen, et al.
Publicado: (2022)

An update on the interaction between COVID-19, vaccines, and diabetic kidney disease
por: Yang, Yang, et al.
Publicado: (2022)

The Role of SGLT2 Inhibitor on the Treatment of Diabetic Retinopathy
por: Sha, Wenjun, et al.
Publicado: (2020)

The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients
por: Tilinca, Mariana Cornelia, et al.
Publicado: (2021)

SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy
por: Li, Na, et al.
Publicado: (2020)

Correction to: Combination therapy of PKCζ and COX-2 inhibitors synergistically suppress melanoma metastasis
por: Zhou, Ping, et al.
Publicado: (2021)

CETP and SGLT2 inhibitor combination therapy improves glycemic control
por: Khomtchouk, Bohdan B., et al.
Publicado: (2023)

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
por: Sands, Arthur T., et al.
Publicado: (2015)

Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2
por: Oranje, Paul, et al.
Publicado: (2019)

The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone
por: Li, Yan-Rong, et al.
Publicado: (2021)

Efficacy of SGLT2 inhibitors as additional treatment in Japanese type 2 diabetic patients: second or third choice?
por: Fujiwara, Makoto, et al.
Publicado: (2022)

Correction: Combined therapy of prednisone and mTOR inhibitor sirolimus for treating retroperitoneal fibrosis
Publicado: (2023)

SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease
por: Kanduri, Swetha R., et al.
Publicado: (2020)

EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors
por: Fernández-Fernandez, Beatriz, et al.
Publicado: (2023)

Correction to: Bazedoxifene as a novel GP130 inhibitor for Colon Cancer therapy
por: Wei, Jia, et al.
Publicado: (2019)

SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes
por: Wheeler, David C., et al.
Publicado: (2020)

A real-world study on SGLT2 inhibitors and diabetic kidney disease progression
por: Liu, Allen Yan Lun, et al.
Publicado: (2022)

SGLT-2 inhibitors and their potential in the treatment of diabetes
por: Rosenwasser, Rebecca F, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_l31kheo0e078mt8333gn5fdqm1